The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | Updates on immunotherapies for myeloma at IMW 2021
Philippe Moreau, MD, Nantes University Hospital, Nantes, France, gives an overview of the latest updates on the use of immunotherapies in the treatment of multiple myeloma. Prof. Moreau talks on advancements in cellular therapies such as chimeric antigen receptor T-cell (CAR-T) therapy, focusing on B-cell maturation antigen (BCMA)-targeting therapies such as idecabtagene vicleucel (ide-cel). Prof. Moreau also shares data from a study exploring ide-cel use in patients who have relapsed on front-line agents, reporting a median progression-free survival (PFS) of 12 months and a median overall survival (OS) of 2 years. Prof. Moreau further talks on preliminary data from the use of ciltacabtagene autoleucel (cilta-cel), another BCMA-targeting therapy, as well as bispecific antibodies. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
